BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

AN2 Therapeutics (ANTX)AN2 TherapeuticsCompany update

MENLO PARK, Calif. --(BUSINESS WIRE)--Sep. 16, 2026-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to Cameron Trenor,

Related news

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ANTXAN2 Therapeutics2026-08-24 11:00 EST

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

SPROSpero Therapeutics2026-09-03 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SCYXSCYNEXIS2026-08-25 23:06 EST

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SCYXSCYNEXIS2026-05-07 01:15 EST

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-09-02 21:01 EST

Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-09-16 21:33 EST

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-08-31 22:00 EST

AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

ANTXAN2 Therapeutics2026-08-24 11:00 EST

AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

Stock data

Close
4.90 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States